Long-term safety and efficacy of nedosiran in patients with PH (PHYOX3): An interim analysis of PH1 patients
John C. Lieske1; Gema Ariceta2; Jaap W. Groothoff3; Graham Lipkin4; Shabbir H. Moochhala5; Gesa Schalk6; Anne-Laure Sellier-Leclerc7; Sara Estupiñan Torres8; Verity Rawson9; Jing Zhou9; Bernd Hoppe10
MATERIALS AVAILABLE
Slide
18:45 - 22:00
PDT
Symposium
Evolving science and clinical management in nephrology: CKD in T2D and primary hyperoxaluria
Matthew Breeggemann; Robert Toto; Lance Sloan; Amy Mottl; David S. Goldfarb
MATERIALS AVAILABLE
Teaser Video
Saturday, 26 October 2024
10:00 - 12:00
PDT
SA-PO651
Publication
Burden of Illness of Primary Hyperoxaluria with Chronic Kidney Disease
David S. Goldfarb1; Jing Voon Chen2; Olivia Li3; Jeffrey R. Skaar3,4; Sandra Salem4; Frank Modersitzki1
MATERIALS AVAILABLE
Slide
Poster
10:00 - 12:00
PDT
SA-PO653
Publication
Nedosiran in Pediatric Patients with PH1 and Relatively Preserved Kidney Function, a phase 2 study (PHYOX8)
David J. Sas1,2,3; Sevcan A. Bakkaloglu4; Vladimir Belostotsky5; Wesley Hayes6; Gema Ariceta7; Jing Zhou8; Verity Rawson8